MORRISTOWN, N.J., Mar 31, 2005 (BUSINESS WIRE) -- PL Thomas (PLT) today announced the results of a new study using its exclusive dietary supplement ingredient, GliSODin(R), demonstrating significant protection against the deleterious effects of the sun. Conducted by French dermatologists over a 60-day period, 150 volunteers participated in this open trial designed to gauge the effect of GliSODin for individuals susceptible to flushing and burns, sun allergy, and other reactions such as pruritus, solar eczema and rashes.
In the study, 86% of the participants experienced significant protection. The report concludes, "GliSODin usage prepares the skin for exposure to the sun and undeniably improves the condition of both the patient's skin and general condition."
The sun gives out energy over a broad spectrum of wavelengths. Ultraviolet (UV) radiation, which has a shorter wavelength than either visible blue or violet light, is a cause of oxidative stress, and is responsible for skin irritation, sunburn and other adverse health effects.
GliSODin, a nutraceutical product that promotes the production of the body's own antioxidants, including super oxide dismutase (SOD), has been shown in several human studies to promote cellular health and protect against damage caused by oxidative stress.
Catherine Laverdet, M.D., previously conducted a pilot study on sun exposure with 15 volunteers. Completed in September 2003, GliSODin demonstrated protection against skin irritation, sunburn and sun allergy. These findings led Dr. Laverdet and a team of 40 French dermatologists to evaluate the effects of GliSODin and sun exposure in 150 patients (130 women and 20 men).
The patients were given 500mg of GliSODin a day 15 days prior to and during sun exposure. The patients sunbathed as usual and continued to use their regular sun screen (Index 20 to 100).
Enrolled patients were split into three different groups and evaluated after 60 days.
-- Group 1: 75 patients who suffer flushes as soon as sun exposure begins or following more or less serious sunburns. In this group, 85% of the patients (64) had no sunburn, 8% (6) had diminished episodes and 6% (5) experienced sunburn.
-- Group 2: 60 patients who experience sun allergic reactions. In this group, 73% of the patients (44) did not experience allergic reaction, 10% (6) had a reduced reaction and 16% (10) experienced an allergic reaction.
-- Group 3: 15 patients with other reactions such as pruritus (severe skin itching), solar eczema and rashes. In this group, 100% of the patients were free from negative reactions.
The participants also completed a questionnaire and reported the following:
-- 110 patients believed that their skin was well prepared for exposure to the sun
-- 76 patients reported that they tanned more with less exposure to the sun
-- 62 patients felt that taking GliSODin speeds up the tanning process
The patients were asked to report any quality-of-life issues that they associated with GliSODin usage. Eighty-eight patients declared their quality of life to have been improved, citing among other benefits increased vitality, improved quality of sleep and alertness, and reduced muscular pain.
The study was sponsored by the manufacturer of GliSODin(R), ISOCELL Nutra, France.
GliSODin(R) is patented and trademarked by ISOCELL Nutra, Paris. It is available in North America as a nutritional raw material exclusively from PL Thomas & Co., Morristown, N.J. Numerous in vivo and human studies support the use of GliSODin in nutritional applications.
PL Thomas & Co., a New Jersey-based ingredient supplier, offers 50 years of innovation in securing reliable, high-quality raw materials for the food/functional food and nutrition industries.